AXGT - Axovant Gene Therapies Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.76
+0.08 (+1.20%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.68
Open6.72
Bid6.69 x 1000
Ask6.77 x 3100
Day's Range6.56 - 6.88
52 Week Range3.81 - 20.80
Volume53,787
Avg. Volume660,270
Market Cap153.998M
Beta (3Y Monthly)1.83
PE Ratio (TTM)N/A
EPS (TTM)-5.71
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.00
Trade prices are not sourced from all markets
  • Benzinga

    Axovant Analyst Turns Bullish Ahead Of Q4 Gene Therapy Data Readouts

    Axovant's multiple opportunities to find an efficacious gene therapy make it an attractive investment ahead of data readouts scheduled for the fourth quarter, Skorney said in a Monday note. Axovant is due to release initial data from the first Type 2 GM1 gangliosidosis patient dosed with AXO-AAV-GM1 in the fourth quarter. The analyst said the simplistic approach used by AXO-AAV-GM1 in gangliosidosis — usage of well-known AAV9 vector and the IV route of administration — improves the chances of its clinical success.

  • GlobeNewswire

    Axovant Announces Corporate Updates and Financial Results for First Fiscal Quarter Ended June 30, 2019

    SUNRISE-PD Phase 2 trial of AXO-LENTI-PD for Parkinson's disease continues to enroll patients in second dose cohort with data expected in the fourth quarter of calendar 2019Data.

  • Immunomedics (IMMU) Posts Wider-Than-Expected Loss in Q2
    Zacks

    Immunomedics (IMMU) Posts Wider-Than-Expected Loss in Q2

    Immunomedics (IMMU) posts wider-than-expected loss and generates no revenues in the second quarter of 2019.

  • Horizon Therapeutics' (HZNP) Q2 Earnings Beat Estimates
    Zacks

    Horizon Therapeutics' (HZNP) Q2 Earnings Beat Estimates

    Horizon (HZNP) beats earnings and sales estimates in the second quarter of 2019.

  • Catalyst's (CPRX) Q2 Earnings and Revenues Beat Estimates
    Zacks

    Catalyst's (CPRX) Q2 Earnings and Revenues Beat Estimates

    Catalyst (CPRX) surpasses earnings and sales estimates in the second quarter of 2019.

  • Geron (GERN) Stock Up Despite Q2 Earnings & Sales Miss
    Zacks

    Geron (GERN) Stock Up Despite Q2 Earnings & Sales Miss

    Geron (GERN) posts a wider-than-expected loss in second-quarter 2019. Operating expenses increase on a year-over-year basis.

  • IVERIC bio's (ISEE) Q2 Loss Narrows, Gene Therapy in Focus
    Zacks

    IVERIC bio's (ISEE) Q2 Loss Narrows, Gene Therapy in Focus

    IVERIC bio (ISEE) second-quarter earnings improve year over year. The company is focusing on developing gene therapies for treating inherited retinal diseases.

  • Clovis (CLVS) Q2 Earnings & Sales Lag Estimates, Shares Down
    Zacks

    Clovis (CLVS) Q2 Earnings & Sales Lag Estimates, Shares Down

    Clovis (CLVS) reports dismal second-quarter 2019 results. The company provides lower-than-expected guidance for product sales in 2019.

  • Axovant (AXGT) Gains As Market Dips: What You Should Know
    Zacks

    Axovant (AXGT) Gains As Market Dips: What You Should Know

    Axovant (AXGT) closed at $6.67 in the latest trading session, marking a +1.52% move from the prior day.

  • Axovant (AXGT) to Post Q1 Earnings: What's in the Cards?
    Zacks

    Axovant (AXGT) to Post Q1 Earnings: What's in the Cards?

    On Axovant's (AXGT) first-quarter fiscal 2019 earnings call, investor focus will be on its progress with the investigational pipeline candidates designed to treat debilitating neurological diseases.

  • Eton's Ophthalmic Solution Candidate Gets CRL, Shares Fall
    Zacks

    Eton's Ophthalmic Solution Candidate Gets CRL, Shares Fall

    Eton's (ETON) partner receives complete response letter for a regulatory application seeking approval of its pipeline candidate, EM-100, as a treatment for ocular itching.

  • Axovant (AXGT) Outpaces Stock Market Gains: What You Should Know
    Zacks

    Axovant (AXGT) Outpaces Stock Market Gains: What You Should Know

    Axovant (AXGT) closed the most recent trading day at $7.38, moving +0.68% from the previous trading session.

  • Will Axovant Sciences Continue to Surge Higher?
    Zacks

    Will Axovant Sciences Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor Axovant Sciences.

  • Sarepta Stock Up Almost 40% This Year So Far: Here's Why
    Zacks

    Sarepta Stock Up Almost 40% This Year So Far: Here's Why

    Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is nearing approval. The company is also developing gene therapies.

  • Perrigo Completes Ranir Acquisition, Raises '19 Guidance
    Zacks

    Perrigo Completes Ranir Acquisition, Raises '19 Guidance

    Perrigo (PRGO) completes previously announced acquisition of Ranir. The company raised guidance for adjusted earnings to include accretion of 10 cents from Ranir.

  • GlobeNewswire

    Axovant Appoints David Nassif as Chief Financial Officer and Expands Board of Directors

    Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announced the appointment of David Nassif as Chief Financial Officer, effective July 1, 2019. In addition, Axovant announced the expansion of its Board of Directors with the addition of Mr. Senthil Sundaram.

  • Is Axovant Gene Therapies Ltd. (AXGT) Going to Burn These Hedge Funds?
    Insider Monkey

    Is Axovant Gene Therapies Ltd. (AXGT) Going to Burn These Hedge Funds?

    "Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]

  • Are Options Traders Betting on a Big Move in Axovant (AXGT) Stock?
    Zacks

    Are Options Traders Betting on a Big Move in Axovant (AXGT) Stock?

    Investors need to pay close attention to Axovant (AXGT) stock based on the movements in the options market lately.

  • GlobeNewswire

    Axovant Announces Poster Presentations at the 5th Congress of the European Academy of Neurology

    Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, announced two posters at the 5th Congress of the European Academy of Neurology (EAN) to be presented by Paul Korner, MD, SVP, Clinical Development and Medical Affairs.

  • InvestorPlace

    Axovant Gene Therapies News: AXGT Stock Soars on Manufacturing Deal

    Axovant Gene Therapies (NASDAQ:AXGT) saw its stock skyrocket on Friday as the company inked a deal with Yposkesi related to the manufacturing of the biopharmaceutical business' experimental treatments.Axovant is partnering up with the French contract development and manufacturing business in order to reserve manufacturing capacity for the company's experimental treatments, granting Axovant preferred access and reserved capacity for viral vector production. The move also gives the company expertise in process development, technology transfer and quality control, per a statement from the biopharma business."This partnership is expected to provide Axovant with sufficient manufacturing capacity to deliver our gene therapies to patients at scale, a key component for the continued development of our gene therapy pipeline," Axovant CEO Pavan Cheruvu said in the company's statement.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAxovant has no manufacturing capacity of its own, which means the business depends on partnerships as it works to bring its first therapies to market. The company currently has agreements with Oxford BioMedica, as well as Nationwide Children's Hospital to supply material.Yposkesi is focused on gene therapy work, and the company has plans in place to double its manufacturing capacity for AAV and lentiviral vectors to 100,000 square feet, per the companies' statement. The brand also plans on creating additional large-scale bioreactors.CEO Alain Lamprove said Yposkesi will seek to help Axovant accelerate the development of its treatments, which includes therapies in clinical testing for Parkinson's disease, GM1 gangliosidosis and GM2 gangliosidosis.AXGT stock is up a whopping 30.9% on Friday following the news. More From InvestorPlace * 7 Value Stocks to Buy for the Second Half * 6 Stocks Ready to Bounce on a Trade Deal * The 7 Best Dow Jones Stocks to Buy for the Rest of 2019 Compare Brokers The post Axovant Gene Therapies News: AXGT Stock Soars on Manufacturing Deal appeared first on InvestorPlace.

  • Options Heat Up on "Undervalued" Drug Stock
    Schaeffer's Investment Research

    Options Heat Up on "Undervalued" Drug Stock

    SVB Leerink thinks the penny stock could triple

  • Benzinga

    Axovant Strikes Gene Therapy Manufacturing Partnership With CDMO

    Axovant Gene Therapies Ltd (NASDAQ: AXGT ) shares were trading higher off the open Thursday after it announced a tie-up with a contract development and manufacturing organization, or CDMO. What Happened ...

  • GlobeNewswire

    Axovant and Yposkesi Sign Strategic Gene Therapy Development and Manufacturing Partnership

    BASEL, Switzerland and CORBEIL-ESSONNES, France, June 20, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announces it has signed a strategic partnership with Yposkesi, a leading Contract Development and Manufacturing Organization (CDMO) for preferred access and reserved capacity for cGMP grade viral vector production. Under this strategic collaboration, Yposkesi will provide expertise in process development, technology transfer, manufacturing scale-up, quality control and quality assurance.

  • Markit

    See what the IHS Markit Score report has to say about Axovant Gene Therapies Ltd.

    Axovant Gene Therapies Ltd NASDAQ/NGS:AXGTView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for AXGT with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding AXGT is favorable, with net inflows of $1.20 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Axovant (AXGT) Upgraded to Strong Buy: Here's Why
    Zacks

    Axovant (AXGT) Upgraded to Strong Buy: Here's Why

    Axovant (AXGT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).